Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and other therapeutic areas. The company's pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.

Enterome

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies S.A.

DBV Technologies is a global clinical stage biopharmaceutical company that develops epicutaneous immunotherapy for food allergies and other immunological diseases. Self-described.

DBV Technologies

DBV Technologies | 16,493 followers on LinkedIn. On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™ | DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.

We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.

This mission drives our commitment to the advancement of treatments for patients and their families.

Vincent DIOSZEGHY

LifeSci Advisors-LS Associates

Will de Groot

Freelance Photographer at Thomas Raffoux Photography

Thomas Raffoux

Chief Medical Officer at Sitryx Therapeutics

Ravi Rao

DBV is proud to sponsor FAACT, Food Allergy & Anaphylaxis Connection Team 's Digital Influencer Summit and tenth annual Global Food Industry and Research Summit. We look forward to connecting with peers to explore how to safely meet the needs of the #FoodAllergy community. Stop by our booth to learn more: https://bit.ly/40CQskp

Today, we reported financial results for the third quarter of 2024. Read the full press release here: https://bit.ly/4hEPzhe

We look forward to joining our #FoodAllergy peers at the upcoming American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, where we will be hosting a product theater on Saturday, October 26. Visit us at our booth to learn more about our potential treatment for those with peanut allergy. Details here: https://bit.ly/3NGNPWZ

We are pleased to announce positive regulatory updates for our investigational product, the Viaskin® Peanut Patch, including guidance on a pathway for Accelerated Approval for toddlers ages 1-3 with #PeanutAllergy . Join our conference call at 5pm ET for more: https://bit.ly/4hfTfpC

Our CMO, Pharis Mohideen , participated in a panel at FARE Neighborhoods Day about using data & research to navigate the landscapes of our neighborhoods to create more equitable futures for those with #FoodAllergies . We're grateful for the opportunity to participate in inspiring dialogue to move toward a more inclusive and healthy future for all.

Our team had the pleasure of connecting with members of the #allergy community for Allergy & Asthma Network 's annual #CorporateCouncil meeting. It was great to come together and discuss ways to empower patients and create a healthier future for all.

🔬 Our innovative technology platform merges science and technology to change the way we think about #allergy treatment. It allows us to explore the potential of the Viaskin® patch and epicutaneous immunotherapy for children with #PeanutAllergy . Learn more here: https://bit.ly/4b5svUE

In case you missed it, KSTP Minnesota explores the development of our investigational pediatric #PeanutAllergy treatment with Dr. Doug McMahon of the Asthma & Allergy Center of Minnesota and our CMO, Dr. Pharis Mohideen, featuring insights from a mother of a peanut-allergic child. Watch here to learn more: https://bit.ly/4guSbhe

Don't miss our lunch symposium at this year's World Allergy Congress. We will discuss our work to advance our lead candidate for the treatment of #PeanutAllergy . Learn more about the congress here: https://bit.ly/3MO4ub1 World Allergy Organization

We are proud to share that we've completed screening for our VITESSE Phase 3 #ClinicalTrial for children ages 4-7 with a #PeanutAllergy . We look forward to further advancing our clinical development program. Read more in our press release: https://bit.ly/4gxNxiD

Metric
Company Name	Biotech 365	Enterome
Symbol
MSH ID	COM:BIOTECH-365	COM:ENTEROME
Market	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Healthcare & Health Services
Industry	Biotechnology Business Services	Biopharmaceuticals
Country	FR
Stage
Employee Count		51
Website	biotech-365.com	enterome.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	68
Web Traffic Growth	-0.57
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:DBV-TECHNOLOGIES

DBV Technologies

Last Close

0.51

22/11 16:35

Market Cap

73.81M

Beta: -

Volume Today

382.51K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue